https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16647
4 Likes
It depends a lot on how the study is done. Obese people might benefit but others do not: No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes 2023
And even in obese people, GLP-1RAs do better than metformin:
- Associations of semaglutide with Alzheimer’s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study 2025
- Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US 2024
4 Likes
Thanks
The other difference above might be that Metformin can help prevent (as in the study Aging Doc) posted vs cannot reverse (or slow) AD once it has gotten going?
The paper concludes “The utility of metformin to prevent dementia was not supported.” so I don’t think metformin can prevent dementia. And if it does it’s probably a weak effect, certainly weaker than SGLT2i and GLP-1RAs (and their combination?).
1 Like
I found it interesting that he had energy markers, what are these?
4 Likes
To be honest it is typical for him. He provides values, but does not explain what the units are. (Obviously percentages don’t have units, but they are percentages of something).
4 Likes